Notice: This company has been marked as potentially delisted and may not be actively trading. Gemphire Therapeutics (GEMP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends GEMP vs. IVA, PBYI, MCRB, SGMT, TELO, SKYE, PYXS, RPTX, IXHL, and LLYShould you be buying Gemphire Therapeutics stock or one of its competitors? The main competitors of Gemphire Therapeutics include Inventiva (IVA), Puma Biotechnology (PBYI), Seres Therapeutics (MCRB), Sagimet Biosciences (SGMT), Telomir Pharmaceuticals (TELO), Skye Bioscience (SKYE), Pyxis Oncology (PYXS), Repare Therapeutics (RPTX), Incannex Healthcare (IXHL), and Eli Lilly and Company (LLY). These companies are all part of the "medical" sector. Gemphire Therapeutics vs. Inventiva Puma Biotechnology Seres Therapeutics Sagimet Biosciences Telomir Pharmaceuticals Skye Bioscience Pyxis Oncology Repare Therapeutics Incannex Healthcare Eli Lilly and Company Gemphire Therapeutics (NASDAQ:GEMP) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, community ranking, dividends, profitability and analyst recommendations. Which has better valuation and earnings, GEMP or IVA? Gemphire Therapeutics has higher earnings, but lower revenue than Inventiva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGemphire TherapeuticsN/AN/A-$23.64MN/AN/AInventiva$15.62M8.79-$119.51MN/AN/A Do analysts rate GEMP or IVA? Inventiva has a consensus target price of $13.25, suggesting a potential upside of 406.69%. Given Inventiva's stronger consensus rating and higher possible upside, analysts clearly believe Inventiva is more favorable than Gemphire Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemphire Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Inventiva 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media favor GEMP or IVA? In the previous week, Inventiva had 11 more articles in the media than Gemphire Therapeutics. MarketBeat recorded 11 mentions for Inventiva and 0 mentions for Gemphire Therapeutics. Gemphire Therapeutics' average media sentiment score of 0.00 beat Inventiva's score of -0.08 indicating that Gemphire Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Gemphire Therapeutics Neutral Inventiva Neutral Is GEMP or IVA more profitable? Inventiva's return on equity of 0.00% beat Gemphire Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gemphire TherapeuticsN/A -419.70% -173.05% Inventiva N/A N/A N/A Do insiders & institutionals believe in GEMP or IVA? 17.5% of Gemphire Therapeutics shares are held by institutional investors. Comparatively, 19.1% of Inventiva shares are held by institutional investors. 22.7% of Gemphire Therapeutics shares are held by insiders. Comparatively, 32.0% of Inventiva shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, GEMP or IVA? Gemphire Therapeutics has a beta of 2.82, meaning that its share price is 182% more volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Does the MarketBeat Community believe in GEMP or IVA? Gemphire Therapeutics received 269 more outperform votes than Inventiva when rated by MarketBeat users. However, 80.00% of users gave Inventiva an outperform vote while only 69.98% of users gave Gemphire Therapeutics an outperform vote. CompanyUnderperformOutperformGemphire TherapeuticsOutperform Votes28969.98% Underperform Votes12430.02% InventivaOutperform Votes2080.00% Underperform Votes520.00% SummaryInventiva beats Gemphire Therapeutics on 10 of the 14 factors compared between the two stocks. Ad Wide Moat ResearchFormer Trump advisor releases terrifying warningGoldman Sachs: 300 Million People Are At Risk The mainstream media are practically ignoring the most important financial story of the decade. Goldman Sachs, the IMF, JP Morgan, Bank of America, and Morgan Stanley have issued warnings. Yet most ordinary Americans have no idea. Now one former Trump advisor is sounding the alarm. “If people knew the full facts, there’d be blood in the streets.” Get the facts and learn how to protect your family now. Get Gemphire Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GEMP vs. The Competition Export to ExcelMetricGemphire TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.25M$6.56B$5.22B$8.83BDividend YieldN/A8.13%5.53%4.08%P/E RatioN/A10.0692.5417.53Price / SalesN/A359.921,233.8096.02Price / CashN/A53.8341.4336.94Price / Book4.3910.597.236.54Net Income-$23.64M$153.02M$119.89M$226.07M Gemphire Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GEMPGemphire TherapeuticsN/A$2.37+0.9%N/A+455.4%$35.25MN/A0.009IVAInventiva2.8364 of 5 stars$2.66-2.9%$14.00+426.3%-34.5%$139.60M$18.91M0.00100Analyst ForecastNews CoverageGap DownPBYIPuma Biotechnology4.2266 of 5 stars$2.91+2.5%$7.00+140.5%-27.5%$139.41M$243.57M6.06185Analyst ForecastMCRBSeres Therapeutics3.4668 of 5 stars$0.73-11.0%$5.08+597.9%-31.4%$138.96M$126.33M-3.17233Analyst UpgradeSGMTSagimet Biosciences2.2882 of 5 stars$4.50-0.4%$21.60+380.0%+29.3%$138.02M$2M0.008TELOTelomir PharmaceuticalsN/A$4.47+6.4%N/AN/A$132.36MN/A0.001Analyst RevisionNews CoverageGap UpHigh Trading VolumeSKYESkye Bioscience1.2578 of 5 stars$4.26-0.7%$18.67+338.7%+171.1%$129.10MN/A0.0011Insider TradePYXSPyxis Oncology1.1517 of 5 stars$2.13-44.2%$10.00+369.5%+35.7%$126.67MN/A-2.0760Analyst ForecastNews CoverageHigh Trading VolumeRPTXRepare Therapeutics2.3535 of 5 stars$2.97+4.6%$10.00+236.7%-42.4%$126.26M$51.13M-1.49180Gap UpIXHLIncannex Healthcare1.1396 of 5 stars$1.96-6.2%N/A+115.2%$124.42M$10,000.00-1.413LLYEli Lilly and Company4.9918 of 5 stars$748.91-0.6%$1,007.94+34.6%+25.7%$710.96B$34.12B80.9643,000Analyst RevisionNews CoveragePositive News Related Companies and Tools Related Companies Inventiva Competitors Puma Biotechnology Competitors Seres Therapeutics Competitors Sagimet Biosciences Competitors Telomir Pharmaceuticals Competitors Skye Bioscience Competitors Pyxis Oncology Competitors Repare Therapeutics Competitors Incannex Healthcare Competitors Eli Lilly and Company Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GEMP) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredReality Check: Are You Prepared for What's Next?Global shifts, like the alliance of BRICS nations pushing for economic independence from the U.S. dollar, and ...Allegiance Gold | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemphire Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemphire Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GEMP Stock Alerts